ES2586947T3 - Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación - Google Patents

Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación Download PDF

Info

Publication number
ES2586947T3
ES2586947T3 ES14164650.5T ES14164650T ES2586947T3 ES 2586947 T3 ES2586947 T3 ES 2586947T3 ES 14164650 T ES14164650 T ES 14164650T ES 2586947 T3 ES2586947 T3 ES 2586947T3
Authority
ES
Spain
Prior art keywords
formula
hemitartrate
therapeutic agent
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14164650.5T
Other languages
English (en)
Spanish (es)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2586947(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ES2586947T3 publication Critical patent/ES2586947T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Molecular Biology (AREA)
ES14164650.5T 2009-11-27 2010-11-24 Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación Active ES2586947T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264748P 2001-01-29
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
ES2586947T3 true ES2586947T3 (es) 2016-10-19

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
ES14164650.5T Active ES2586947T3 (es) 2009-11-27 2010-11-24 Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación
ES10785289T Active ES2493940T5 (es) 2009-11-27 2010-11-24 Una forma amorfa y una forma cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
ES16175117T Active ES2754398T3 (es) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) como inhibidor de glucosilceramida-sintasa para uso en un método de tratamiento de la enfermedad de fabry o de gaucher, comprendiendo el método ajustar la dosis terapéutica individual al metabolismo P-450 del paciente
ES19182732T Active ES2875382T3 (es) 2009-11-27 2010-11-24 Composición farmacéutica del inhibidor de glucosilceramida sintasa Eliglustat para el tratamiento de la enfermedad de Gaucher, que comprende ajustar la dosis terapéutica individual al metabolismo de P450 del paciente

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES10785289T Active ES2493940T5 (es) 2009-11-27 2010-11-24 Una forma amorfa y una forma cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
ES16175117T Active ES2754398T3 (es) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) como inhibidor de glucosilceramida-sintasa para uso en un método de tratamiento de la enfermedad de fabry o de gaucher, comprendiendo el método ajustar la dosis terapéutica individual al metabolismo P-450 del paciente
ES19182732T Active ES2875382T3 (es) 2009-11-27 2010-11-24 Composición farmacéutica del inhibidor de glucosilceramida sintasa Eliglustat para el tratamiento de la enfermedad de Gaucher, que comprende ajustar la dosis terapéutica individual al metabolismo de P450 del paciente

Country Status (40)

Country Link
US (6) US11458119B2 (enExample)
EP (5) EP3896069A1 (enExample)
JP (6) JP2013512252A (enExample)
KR (6) KR20180049255A (enExample)
CN (5) CN112521366A (enExample)
AR (3) AR079152A1 (enExample)
AU (3) AU2010324810B2 (enExample)
BR (1) BR112012012947B8 (enExample)
CA (3) CA3140959A1 (enExample)
CL (2) CL2012001348A1 (enExample)
CR (1) CR20120277A (enExample)
CY (3) CY1115880T1 (enExample)
DK (3) DK2796457T3 (enExample)
DO (2) DOP2012000141A (enExample)
EA (3) EA029990B1 (enExample)
EC (2) ECSP12011926A (enExample)
ES (4) ES2586947T3 (enExample)
GT (1) GT201200161A (enExample)
HR (3) HRP20140780T4 (enExample)
HU (2) HUE029371T2 (enExample)
IL (4) IL310635A (enExample)
LT (2) LT2796457T (enExample)
MA (1) MA33838B1 (enExample)
ME (1) ME02477B (enExample)
MX (2) MX358345B (enExample)
MY (2) MY160542A (enExample)
NI (1) NI201200096A (enExample)
NZ (3) NZ625712A (enExample)
PE (2) PE20171255A1 (enExample)
PH (2) PH12015502514B1 (enExample)
PL (4) PL3133070T3 (enExample)
PT (4) PT2796457T (enExample)
RS (3) RS54978B1 (enExample)
SG (2) SG10201407881WA (enExample)
SI (3) SI3133070T1 (enExample)
SM (1) SMT201600273B (enExample)
TN (1) TN2012000237A1 (enExample)
TW (3) TWI586663B (enExample)
UA (1) UA113491C2 (enExample)
WO (1) WO2011066352A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
LT2854910T (lt) 2012-06-01 2020-05-25 Icahn School Of Medicine At Mount Sinai Ceramido lygiai infekcijos gydymo ir prevencijos metu
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP3046920B1 (en) * 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017087409A1 (en) 2015-11-18 2017-05-26 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
CA3067044A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
EP3664798B1 (en) 2017-08-08 2025-10-29 Amneal Pharmaceuticals LLC Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
SG11202004954YA (en) * 2017-12-15 2020-06-29 Genzyme Corp Methods for treating gaucher disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
CA3101097A1 (en) * 2018-05-27 2019-12-05 Bioasis Technologies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
AU2021455177B2 (en) * 2021-07-05 2025-01-09 Asceneuron Sa Medicaments comprising glycosidase inhibitors
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
ATE197672T1 (de) 1993-08-13 2000-12-15 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
WO1995021175A1 (en) 1994-02-02 1995-08-10 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
JP3850437B2 (ja) 1994-06-10 2006-11-29 生化学工業株式会社 ２−アシルアミノプロパノール化合物及び医薬組成物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
DE69935720T2 (de) 1998-07-27 2007-12-27 The Johns Hopkins University Diamino-propanol-verbindungen zur behandlung von ischaemien
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
PL358548A1 (en) 2000-04-24 2004-08-09 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrate
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
CN1630720A (zh) 2001-01-18 2005-06-22 默克专利有限公司 具有葡糖脑苷脂酶活性的双功能融合蛋白
DK2067775T3 (da) * 2001-07-16 2012-07-16 Genzyme Corp N-acylsphingosinglucosyltransferase-inhibitor
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
JP4316203B2 (ja) 2001-08-08 2009-08-19 トビラ セラピューティクス インク 二環性化合物、その製造法および用途
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
KR20070054246A (ko) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
AU2005293290A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
EP1948655A1 (en) * 2005-10-03 2008-07-30 Mallinckrodt, Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
PT2032134E (pt) * 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
US20080175908A1 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
EP2142197A4 (en) * 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
CA2685332A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
CA2718887A1 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
KR101766931B1 (ko) 2009-11-27 2017-08-09 아드베리오 파마 게엠베하 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US9006270B2 (en) 2011-06-21 2015-04-14 Novartis Ag Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
TWI586663B (zh) 2017-06-11
DK3133070T3 (da) 2019-11-11
ECSP12011926A (es) 2012-07-31
ME02477B (me) 2017-02-20
JP6452635B2 (ja) 2019-01-16
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
US11458119B2 (en) 2022-10-04
MA33838B1 (fr) 2012-12-03
SI2504332T2 (sl) 2021-08-31
PT2504332E (pt) 2014-09-02
MY160542A (en) 2017-03-15
DK2504332T3 (da) 2014-08-25
HRP20140780T4 (hr) 2021-08-06
RS53503B1 (sr) 2015-02-27
SG10201800136QA (en) 2018-02-27
ECSP18063798A (es) 2020-02-28
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
CY1117996T1 (el) 2017-05-17
MY192644A (en) 2022-08-29
AR079152A1 (es) 2011-12-28
HUE045784T2 (hu) 2020-01-28
PT3599237T (pt) 2021-04-28
KR20220162824A (ko) 2022-12-08
NZ600155A (en) 2014-10-31
EA201890254A2 (ru) 2018-10-31
AU2017265180A1 (en) 2017-12-14
BR112012012947B1 (pt) 2021-04-06
US20210369672A1 (en) 2021-12-02
TWI656873B (zh) 2019-04-21
CN102712629A (zh) 2012-10-03
CA2781676C (en) 2020-05-05
ES2493940T5 (es) 2021-11-23
PH12015502514A1 (en) 2016-08-15
CA3075788A1 (en) 2011-06-03
AU2010324810A1 (en) 2012-06-07
HRP20140780T1 (en) 2014-11-07
IL260299A (en) 2018-08-30
CY1122698T1 (el) 2021-03-12
NI201200096A (es) 2012-10-30
NZ715108A (en) 2017-06-30
CN112521367B (zh) 2024-01-02
WO2011066352A1 (en) 2011-06-03
JP2020189873A (ja) 2020-11-26
PH12012501048A1 (en) 2013-02-04
IL310635A (en) 2024-04-01
HUE029371T2 (en) 2017-02-28
PT3133070T (pt) 2019-11-11
JP7150528B2 (ja) 2022-10-11
SI2504332T1 (sl) 2014-09-30
CL2016002589A1 (es) 2017-05-19
KR20150125734A (ko) 2015-11-09
WO2011066352A8 (en) 2011-08-11
IL219892A0 (en) 2012-07-31
PL2796457T3 (pl) 2017-04-28
LT3133070T (lt) 2019-11-11
CA3075788C (en) 2021-12-21
BR112012012947B8 (pt) 2021-05-25
CN102712629B (zh) 2016-10-12
SG10201407881WA (en) 2015-01-29
PL3599237T3 (pl) 2021-09-27
LT2796457T (lt) 2016-09-12
EP2796457A1 (en) 2014-10-29
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
CY1115880T1 (el) 2017-01-25
CN112521367A (zh) 2021-03-19
CN112521366A (zh) 2021-03-19
US20130137743A1 (en) 2013-05-30
PL2504332T5 (pl) 2021-08-23
JP2019001809A (ja) 2019-01-10
US12465586B2 (en) 2025-11-11
AR121612A2 (es) 2022-06-22
JP2016138124A (ja) 2016-08-04
MX381242B (es) 2025-03-12
HK1172031A1 (en) 2013-04-12
AU2016202591B2 (en) 2017-11-30
GT201200161A (es) 2014-01-27
EA201592195A1 (ru) 2016-04-29
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
US20160166542A1 (en) 2016-06-16
JP2013512252A (ja) 2013-04-11
EA023923B1 (ru) 2016-07-29
TN2012000237A1 (en) 2013-12-12
PH12015502514B1 (en) 2022-07-29
IL283935A (en) 2021-07-29
AU2017265180B2 (en) 2019-08-01
DOP2012000141A (es) 2012-09-30
EA201890254A3 (ru) 2019-02-28
JP2023116764A (ja) 2023-08-22
EA029990B1 (ru) 2018-06-29
US20230172903A1 (en) 2023-06-08
TW201130822A (en) 2011-09-16
ES2493940T3 (es) 2014-09-12
RS54978B1 (sr) 2016-11-30
US20160120842A1 (en) 2016-05-05
TW201639562A (zh) 2016-11-16
KR20180049255A (ko) 2018-05-10
EP2504332B2 (en) 2021-03-17
ES2875382T3 (es) 2021-11-10
CL2012001348A1 (es) 2012-08-24
EP3133070A1 (en) 2017-02-22
KR20120115972A (ko) 2012-10-19
SMT201600273B (it) 2016-08-31
HRP20191647T1 (hr) 2019-12-13
MX2012006083A (es) 2012-06-19
TW201737910A (zh) 2017-11-01
SI3133070T1 (sl) 2019-11-29
JP2015212291A (ja) 2015-11-26
EP3133070B1 (en) 2019-08-14
HK1203485A1 (en) 2015-10-30
EP3896069A1 (en) 2021-10-20
CA2781676A1 (en) 2011-06-03
US10888547B2 (en) 2021-01-12
DOP2016000250A (es) 2017-02-15
UA113491C2 (xx) 2017-02-10
JP6370264B2 (ja) 2018-08-08
PL2504332T3 (pl) 2014-10-31
SI2796457T1 (sl) 2016-10-28
CN105753846B (zh) 2019-11-15
ES2754398T3 (es) 2020-04-17
KR20200013105A (ko) 2020-02-05
EP3599237B1 (en) 2021-03-24
EP2504332B1 (en) 2014-06-04
RS53503B2 (sr) 2021-07-30
EP2796457B1 (en) 2016-05-18
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
KR20250005503A (ko) 2025-01-09
EP2504332A1 (en) 2012-10-03
DK2796457T3 (en) 2016-08-29
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
CN105777707B (zh) 2020-10-13
EA201270646A1 (ru) 2013-01-30
PL3133070T3 (pl) 2020-01-31
PE20171255A1 (es) 2017-08-28
CA3140959A1 (en) 2011-06-03
PT2796457T (pt) 2016-07-14
DK2504332T4 (da) 2021-06-07
EP3599237A1 (en) 2020-01-29
BR112012012947A2 (pt) 2017-03-01
HRP20161038T1 (hr) 2016-10-21
RS59543B1 (sr) 2019-12-31

Similar Documents

Publication Publication Date Title
ES2586947T3 (es) Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación
HK40062640A (en) Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
HK40021462A (en) Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
HK40021462B (en) Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
HK1234743B (en) Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
HK1203485B (en) Genz 112638 for treating gaucher or fabry disease in combination therapy
HK1172031B (en) An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase